Equity Incentive Plans (Tables)

6 Months Ended

Jun. 30, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Stock Option Plans

A summary of the status of the Company’s option plans as of June 30, 2017 and changes during the period then ended is presented below: 

	Six months ended June 30, 2017
	Unaudited
	Number of options			Weighted average exercise price
Outstanding at beginning of year		11,377,354		$	9.76
Granted		4,757,238			9.25
Exercised		(639,902	)		2.13
Forfeited and cancelled		(205,370	)		12.65
Outstanding as of June 30, 2017		15,289,320			9.88
Exercisable options		6,722,358			7.49
Vested and expected to vest		15,289,320		$	9.88

Schedule of RSU's

A summary of the status of the Company’s RSUs as of June 30, 2017 and changes during the period then ended is presented below: 

	Six months ended June 30, 2017
	Unaudited
	Number of RSUs		Weighted average grant date fair value price
Unvested at beginning of year		-	$	-
Granted		1,661,619		9.64
Vested		-		-
Forfeited and cancelled		-		-
Unvested as of June 30, 2017		1,661,619	$	9.64

Schedule of Fair Value of Equity Based Awards Using Black-Scholes Option Pricing Model

The fair value of equity-based awards was estimated using the Black-Scholes option-pricing model for all grants with the following underlying assumptions: 

	Six months ended June 30,			Year ended December 31,
	2017	2016		2016
	Unaudited			Audited
Stock Option Plans
Expected term (years)	5.5-6.25	6.25		6.25
Expected volatility	56.74%-59.15%	59.80%-61.65%		58.40%-61.70%
Risk-free interest rate	1.99%-2.23%	1.23%-1.88%		1.23%-1.88%
Dividend yield	0.00%	0.00%		0.00%
ESPP
Expected term (years)	0.50		-	0.42
Expected volatility	82.00%		-	70.45%
Risk-free interest rate	0.62%		-	0.40%
Dividend yield	0.00%		-	0.00%

Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards

The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and six months ended June 30, 2017 and 2016 and the year ended December 31, 2016 was:

	Three months ended June 30,				Six months ended June 30,				Year ended December 31,
	2017		2016		2017		2016		2016
	Unaudited				Unaudited				Audited
Cost of revenues	$	131	$	170	$	274	$	311	$	623
Research, development and clinical trials		811		839		1,673		1,602		3,155
Sales and marketing		1,735		1,349		2,390		2,639		5,111
General and administrative		4,893		3,279		7,794		6,541		12,552
Total share-based compensation expense	$	7,570	$	5,637	$	12,131	$	11,093	$	21,441